Orthotopic cardiac transplantation in two patients with previous malignancy

Hinkamp, Thomas J.; Sullivan, Henry J.; Bakhos, Mamdouh; Grieco, John; Pifarré, Roque

doi:10.1016/0003-4975(91)91033-r

Cited by 7 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results support the opinion that a history of malignancy is not an absolute contraindication for cardiac transplantation [13][14][15][16][17]. Careful selection of the patients is, however, required with respect to the form of presentation, histology, extent of the tumor, the tumorfree interval at the time of transplant evaluation and the life expectancy under the current optimal treatment of the tumor.…”

Section: Discussionsupporting

confidence: 86%

“…A pre-existing malignancy may carry the risk of recurrent or de novo tumors due to therapeutic immunosuppression and possible consequent deficient immunomodulation. However, longterm follow-up in carefully selected groups of patients undergoing orthotopic heart transplantation with pretransplant neoplastic disease has been described [13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pretransplant malignancy in candidates and posttransplant malignancy in recipients of cardiac transplantation

Oechslin¹,

Kiowski²,

Schneider³

et al. 1996

Annals of Oncology

View full text Add to dashboard Cite

SummaryBackground: Malignancy is generally considered a contraindication for cardiac transplantation, whereas secondary malignancy has been described under chronic immunosuppression.Patients and methods: We report here the frequency of malignancy encountered among the 495 patients evaluated at our cardiac transplant centre as well as the incidence and the course of post-transplant malignancy among 129 consecutive patients who underwent cardiac transplantation, with a subsequent minimum follow-up of 6 months.Results: A total of 10 out of 495 patients (2%) evaluated for heart transplantation presented with a history of previous malignancy: 3 of them underwent transplantation (2 survive,

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Pretransplant malignancy in candidates and posttransplant malignancy in recipients of cardiac transplantation

Oechslin¹,

Kiowski²,

Schneider³

et al. 1996

Annals of Oncology

View full text Add to dashboard Cite

show abstract

“…In the case of heart transplant (HT), the incidence of post‐HT neoplasm is higher than among recipients of other organs and is a strong limitation of long‐term survival . Previous neoplasms seem to increase the already high risk of post‐HT tumors; however, successful cases of HT in patients with previous malignancies have been reported since the 1990s .…”

Section: Introductionmentioning

confidence: 99%

Cancer Incidence in Heart Transplant Recipients With Previous Neoplasia History

Delgado

Alonso‐Pulpón

Mirabet

et al. 2016

American Journal of Transplantation

View full text Add to dashboard Cite

Neoplasm history increases morbidity and mortality after solid organ transplantation and has disqualified patients from transplantation. Studies are needed to identify factors to be considered when deciding on the suitability of a patient with previous tumor for heart transplantation. A retrospective epidemiological study was conducted in heart transplant (HT) recipients (Spanish Post-Heart Transplant Tumor Registry) comparing the epidemiological data, immunosuppressive treatments and incidence of post-HT tumors between patients with previous malignant noncardiac tumor and with no previous tumor (NPT). The impact of previous tumor (PT) on overall survival (OS) was also assessed. A total of 4561 patients, 77 PT and 4484 NPT, were evaluated. The NPT group had a higher proportion of men than the PT group (p < 0.001). The incidence of post-HT tumors was 1.8 times greater in the PT group (95% confidence interval [CI] 1.2-2.6; p < 0.001), mainly due to the increased risk in patients with a previous hematologic tumor (rate ratio 2.3, 95% CI 1.3-4.0, p < 0.004). OS during the 10-year posttransplant period was significantly lower in the PT than the NPT group (p = 0.048) but similar when the analysis was conducted after a first post-HT tumor was diagnosed. In conclusion, a history of PT increases the incidence of post-HT tumors and should be taken into account when considering a patient for HT.

show abstract

“…In this case, freedom from tumor for 1 year and 7 months allowed heart transplantation to be performed with subsequent immunosuppression and without tumor recurrence to date, 1 year and 9 months later. Despite the promising long-term prognosis, 1,3,5 close posttransplantation follow-up focusing on tumor recurrence will remain necessary. In our case, long-term VAD support allowed the patient to be listed for heart transplantation after she had reached a status of transplantability.…”

Section: Discussionmentioning

confidence: 99%